The MHRA is undertaking a review of UK medicines legislation. As part of this review, we have been looking at the provisions which relate to the product licences of right (PLR) regime and homeopathy.
We have already written directly to the main organisations and representative bodies informally to seek their views on our initial thinking in this area. We are now writing more widely to seek further views about the likely regulatory impact and any implications not so far identified, again on an informal basis.
Comments should be sent to email@example.com
The deadline for comments is 18 February 2011.